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BSTRACT
Background:
 
It is known that the symptoms of allergic
rhinitis can significantly reduce the quality of life of the
patient. One of such typical symptoms of allergic rhin-
itis is nasal obstruction. Nasal obstruction is currently
thought to be closely related to the presence and
abundance of lipid mediators, such as leukotriene
and  thromboxane (TX) A
 
2
 
. The novel drug rama-
troban, a TXA
 
2
 
 receptor antagonist, which has been
developed by Bayer Yakuhin Ltd. (Osaka, Japan), has
been demonstrated, in clinical trials, to improve nasal
obstruction in the treatment of patients with allergic
rhinitis and it has recently become commercially
available.
 
Methods:
 
In the present study, ramatroban was
administered for 28 days to 10 patients who were
diagnosed with perennial allergic rhinitis but were
untreated. Changes in self-reported symptom scores
and 
 
in vivo
 
 allergic reaction parameters were assessed
during three observational periods.
 
Results:
 
From baseline scores, all three symptom
scores after 28 days treatment with ramatroban
declined clearly in all patients, except for one patient
who suffered a cold during the study period and had
aggravated rhinorrhea and nasal obstruction as a
result. The concentrations of histamine and TXB
 
2
 
 (a
metabolite of TXA
 
2
 
) in the nasal fluid induced by antigen
challenge after the 28 day treatment period also
decreased in most subjects compared with concentra-
tions during the pretreatment period. The symptom
scores for nasal obstruction during the pretreatment
period were correlated with the concentration of TXB
 
2
 
in antigen-induced nasal fluid.
 
Conclusions:
 
The present study reconfirmed the clini-
cal efficacy of a post-marketed drug, namely rama-
troban, in the treatment of allergic rhinitis. In addition,
the results suggest that ramatroban suppressed the
secretion of chemical mediators in nasal that are
thought to be involved in the allergic reaction in
patients with perennial allergic rhinitis.
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I
 
NTRODUCTION
 
The first step in an allergic reaction is the release of
histamine and various lipid mediators derived from ara-
chidonic acid via antigen-stimulated mast cells in mucous
membranes. Although histamine is predominantly res-
ponsible for sneezing and nasal discharge, various sub-
stances, such as lipid mediators, are involved in nasal
obstruction in a complex manner.
 
1
 
 The reaction site is
considered to be blood vessels in the nasal mucosa.
 
2
 
One study
 
3
 
 that investigated the mediators involved in
the development of nasal obstruction reported that when
various mediators were sprinkled on the nasal mucosa,
the resistance of the nasal cavity started to increase. The
major mediators that were identified in the study as con-
tributors to nasal obstruction included histamine, leuko-
triene, platelet-activating factor and prostaglandin D
 
2
 
.
In other studies,
 
4,5
 
 it was reported that thromboxane (TX)
A
 
2
 
 also played an important role in the development
process of nasal obstruction. It is also known that lipid
mediators are released not only from mast cells, but also
from eosinophils and that they are involved in the late-
phase inflammatory reaction.
 
1
 
Ramatroban is a selective TXA
 
2
 
 receptor antagonist
that was developed by Bayer AG (Leverkusen, Germany)
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and is now licensed for use in the treatment of allergic
rhinitis by Bayer Yakuhin Ltd (Osaka, Japan) in Japan.
Pharmacologically, ramatroban suppresses the promo-
tion of vascular permeability and infiltration of eosino-
phils and its efficacy has been proven clinically for
treating patients with allergic rhinitis.
 
6
M
 
ETHODS
 
The clinical study was conducted at Sekino Clinical
Pharmacology Institute (CPI). Prior to the study, the study
protocol was reviewed and approved by the institutional
review board at Sekino CPI.
 
Subjects
 
Ten patients were enrolled into the study. These patients
were diagnosed with perennial allergic rhinitis but were
untreated at diagnosis. All patients gave written informed
consent to participate in the study. The diagnosis of
perennial allergic rhinitis was confirmed on the basis
of a positive history of typical symptoms of allergic
rhinitis, +2 RAST scores and a positive allergic response
to house dust mite in any of an anterior rhinoscope
examination, nasal eosinopilia test, skin test or nasal
provocation test.
 
Methodology
 
The study consisted of three observational periods: (i) a
period of 7 days before initiating medication (pretreatment
period: days 1–7); (ii) a period of 21 days with study
medication (treatment period: days 8–28); and (iii) a
period after completing medication (post-treatment period:
days 29–32). During the treatment period, ramatroban
 
Table 1
 
Evaluation criteria for determination of the symptom score
Score (points) 
4 3 2 1 0
Sneezing attacks*
 
≥ 
 
21 20–11 10–6 5–1 0
Nasal discharge†
 
≥ 
 
21 20–11 10–6 5–1 0
Nasal obstruction Complete nasal 
obstruction all 
day
Nasal obstruction severe 
and breathing through 
the mouth performed 
for a considerable time
Nasal obstruction marked 
and breathing thorough 
the mouth performed 
several times a day
No breathing 
through the mouth, 
but nasal obstruction 
present
No nasal 
obstruction
 
*Mean no. attacks per day.
 
†
 
Mean no. nose blows per day.
 
Table 2
 
Symptom score
Sneezing attack or secretion score 
4 3 2 1 0
Nasal obstruction score
4 4 4 4 4 4
3 4 3 3 3 3
2 4 3 2 2 2
1 4 3 2 1 1
0 4 3 2 1 0
 
Table 3
 
Evaluation criteria for the reactivity of nasal antigen challenge test
Reactivity 
+++ ++ + –
No. symptoms 3 3 2 0
No. sneezing episodes
 
≥ 
 
6
 
≤ 
 
5 Not counted
 
Reactivity is evaluated based on the number of symptoms (sneezing, nasal discharge and nasal obstruction) and the number of sneezing
episodes.
In determining the number of sneezing episodes, a single sneeze in 5 min was denoted as one episode in the challenge test.
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(75 mg tablet, p.o.) was administered twice daily, once
after breakfast and once in the evening. No concomitant
drugs were allowed during the study period.
Evaluations
By using a patient diary, the severity of nasal symptoms,
such as sneezing, rhinorrhea and nasal obstruction, was
scored by patients each day during the study period
in accordance with the Severity Classification of the
Clinical Practice Guideline for Nasal Allergy and the
Symptom Score (Table 1).7 The average scores for the
three evaluation periods (days 1–7, 22–28 (the last 7
days of the treatment period) and 29–32) were used for
evaluation analyses as representations of the symptom
severity during the pretreatment, treatment and post-
treatment periods, respectively. Changes in average
scores for individual patients during the three evaluation
periods were determined.
In addition to the patient diary for daily symptom
scores, nasal antigen challenge tests were performed
using house dust mite-extracted paper discs (dry weight
250 µg/mL). The tests were conducted with all subjects
at the beginning of the pretreatment period (day 1) and
at the end of the post-treatment period (day 32) to assess
the effect of ramatroban on nasal reactions. Assessments
were performed by comparing the two test results in terms
of reactivity (Table 2), the volume of nasal fluid, nasal
cavity resistance (Table 3) and the concentration levels of
histamine and TXB2 in the nasal fluid.
Five minutes after challenge, reactivity was assessed,
nasal fluid was collected directly from both nostrils by
suction and the resistance of the nasal cavity was meas-
ured with a rhinomanometer (Rhinorrheograph MPR-
3100; Nihon Kohden, Tokyo, Japan).
The nasal fluid sampled was mixed with dithiothreitol
(500 µL of 0.05% dithiothreitol in 0.01 mol/L phosphate-
buffered saline) in order to resolve mucin and samples
were centrifuged at 400 g for 10 min. Then, the cell-free
supernatant was extracted and stored at –20°C for future
analyses of histamine and TXB2.
Histamine and TXB2 assays8,9
Histamine was quantified using radioimmunoassay by
competitively binding acylated histamine and [125I]-
labeled acylated histamine to stabilized antihistamine
mouse monoclonal antibody.
The prostanoid in the samples was bound to an octa-
desilsilsyl silica carrier under acidic conditions and
protein and lipids were removed.10,11 Prostanoid was
Fig. 1 Average symptom scores during the three observa-
tional periods for each individual patient for (a) sneezing,
(b) rhinorrhea and (c) nasal obstruction. The three observational
periods during the study consisted of: (i) a period of 7 days
before initiating medication (pretreatment period: days 1–7);
(ii) a period of 21 days with the study medication (treatment
period: days 8–28); and (iii) a period after completing medica-
tion (post-treatment period: days 29–32).
 134 K OHKUBO AND M GOTOH
 
eluted from the carrier with ethyl acetate. Thromboxane
B
 
2
 
 antibody was added to the eluate to react with the
antigen. The concentration of radioactivity in the antigen–
antibody reaction product was used to determine con-
centration of TXB
 
2
 
.
 
Statistical analysis
 
Statistical analysis was performed using the Wilcoxon
signed-ranks test and all results are expressed as the
mean 
 
±
 
 SD.
 
R
 
ESULTS
 
Nasal symptoms
 
Changes in symptom scores during the three evaluation
periods were assessed for each symptom in individual
subjects (Fig. 1). Compared with the pretreatment period,
the score for sneezing during the treatment period
decreased in all subjects. In addition, except for one
subject whose symptoms were aggravated due to a cold,
in nine other subjects the same downward trend was
observed for nasal obstruction and rhinorrhea scores
during the treatment period.
After finishing treatment with ramatroban, in gen-
eral, the symptoms that had been improved during the
treatment period did not revert to levels seen during
the pretreatment period, but remained as low as during
the treatment period.
 
Nasal antigen challenge test
 
In eight of 10 patients, a lesser degree of reactivity to
antigen challenge was recorded on day 32 compared
with day 1. The volume of nasal fluid collected was also
decreased or unchanged in the majority patients when
results from day 32 and day 1 were compared. How-
ever, the resistance of the nasal cavity decreased in
fewer patients than did reactivity and volume of nasal
fluid (Table 4).
 
Concentration of mediators in nasal fluid
 
The concentrations of histamine and TXB
 
2
 
 detected in
the nasal fluid collected following antigen challenge
tests in the post-treatment period were lower than
concentrations in the nasal fluid during the pretreatment
period in seven and eight patients, respectively (Fig. 2).
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The concentrations of histamine and TXB2 in the nasal
fluid sampled at two points are shown in Fig. 2. The
concentrations of histamine and TXB2 after treatment with
ramatroban decreased from levels seen during the pre-
treatment period in eight and seven subjects, respectively.
Median values of the concentration for both histamine
and TXB2 show a downward trend, but no significant
difference was detected (P = 0.492 and P = 0.332,
respectively).
Correlation of three individual nasal symptoms with
the concentration of histamine and TXB2 was also investi-
gated during the pre- and post-treatment periods, inde-
pendently. Among six analyses, as shown in Fig. 3, a
positive correlation was shown only for nasal obstruction
and TXB2 concentration during the pretreatment period.
Other analyses did not reach statistical significance.
DISCUSSION
Ramatroban, a novel TXA2 receptor antagonist, has
been investigated in a series of clinical trials to confirm
its efficacy in the treatment of patients with allergic
rhinitis12 and it is now available for daily use in Japan.
The efficacy of ramatroban in improving nasal obstruc-
tion was of particular attraction to physicians, who
often face difficulties in relieving patients from nasal
obstruction.
Terada 
 
et al.,6 who conducted antigen challenge tests
with allergic rhinitis patients treated with ramatroban and
measured changes in nasal cavity volume, reported that
ramatroban significantly suppressed nasal obstruction
within 2 h after administration. They also reported that
the albumin concentration in the nasal fluid and a vas-
cular permeability index were decreased following the
administration of ramatroban. In another study,13 which
examined the migration of cells involved in nasal obstruc-
tion, it was confirmed that ramatroban lessened both the
eosinophil count and the concentration of eosinophil cat-
ionic protein in nasal wash water. These results strongly
support the clinical efficacy of ramatroban in improving
nasal obstruction.
To further investigate the effects of ramatroban, we
performed a clinical investigation with two major objec-
tives. One of the objectives was to reconfirm the efficacy
of ramatroban by comparing symptom levels during the
pretreatment period with those after 4 weeks treatment
with ramatroban. The other objective of the study was to
determine the relationships between symptoms and the
secretion of chemical mediators in the nasal fluid, namely
histamine and TX, which are known to provoke allergic
reactions in patients with allergic rhinitis.
Of 10 untreated male patients with moderate to
severe perennial allergic rhinitis who were administered
ramatroban for 28 days, nine experienced an improve-
ment in nasal obstruction. An interesting observation was
that the scores for nasal obstruction came were reduced
at an earlier stage of the treatment period than expected
(data not shown). In parallel with the improvement in
nasal obstruction, scores for sneezing and a runny nose
Fig. 2 (a) Histamine and (b) thromboxane B2 concentrations in nasal discharge induced by nasal antigen challenge during the
pretreatment and follow-up periods after ramatroban treatment.
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Fig. 3 Correlation of nasal symptoms, namely sneezing (a,b), rhinorrhea (c,d) and nasal obstruction (e,f), and concentrations of
histamine (a,c,e) and thromboxane B2 (b,d,f) in nasal discharge induced by nasal antigen challenge during the pretreatment period
(; -----) and during follow up (; –––––). The regression equations for the pretreatment and follow-up periods are as follows:
(a) y = –0.0023x + 1.9084 (R2 = 0.0623) and y = 0.0008x + 0.7158 (R2 = 0.0332), respectively; (b) y = 0.0001x + 1.7121
(R2 = 0.001) and y = 0.0007x + 0.6105 (R2 = 0.1423), respectively; (c) y = –0.0024x + 2.2134 (R2 = 0.0399) and
y = 0.0016x + 1.2414 (R2 = 0.034), respectively; (d) y = 0.0002x + 2.0073 (R2 = 0.0008) and y = 0.0014x + 1.0426
(R2 = 0.1512); (e) y = 0.0029x + 0.8488 (R2 = 0.0758) and y = 0.003x + 0.6888 (R2 = 0.1339), respectively; and
(f) y = 0.0037x + 0.2575 (R2 = 0.5003) and y = 0.0006x + 0.76448 (R2 = 0.0299), respectively.
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also started decreasing at around day 3 and became
stable around day 10. As a result, similar score changes
in terms of time to onset and improvement tendency were
seen across the three symptoms. Another finding was that
ramatroban was effective not only in improving nasal
obstruction, which was more or less expected from its
mode of action and the results of clinical trials already
reported,12 but also in relieving sneezing and rhinorrhea
and that the effect of ramatroban on these two symptoms
was maintained even during the post-treatment period in
the majority of patients.
To investigate the relationships between symptoms
and the secretion of chemical mediators in the nasal
fluid, an antigen challenge test was conducted before
and after the treatment period. Thromboxane is thought
to be involved in the process of developing nasal obstruc-
tion in patients with perennial allergic rhinitis and,
because ramatroban is a TXA2 receptor antagonist, it was
predicted that TXB2 would have been more sensitively
influenced than histamine by treatment with ramatroban.
However, the concentration of histamine in antigen-
induced nasal discharge decreased to the same extent as
did the concentration of TXB2, which was in contrast with
the prediction prior to the study.5 With regard to the
relationships of the concentrations of the mediators and
clinical symptoms recorded in the patient diary, a statis-
tical correlation was found only for nasal obstruction
scores and TXB2 concentration during the pretreatment
period; no other combinations between any of the
symptom scores and the concentration of histamine or
TXB2 during either the pre- or post-treatment period were
correlated.
The results of the present study indicate that the TXA2
receptor antagonist ramatroban can be used not only for
allergic rhinitis patients with nasal obstruction, but also
for those patients with sneezing and a runny nose in
addition to nasal obstruction. These findings in perennial
allergic rhinitis are in line with a report by Suzaki et al. that
ramatroban effectively improved severe sneezing and
rhinorrhea in patients with seasonal allergic rhinitis in a
randomized study.14 Based on the antigen challenge test
results, it can be considered that the decrease in the
concentration of TXB2 produced by ramatroban may
cause alterations in the nasal mucosa that resulted in a
decrease in the total level of mast cell-related mediators
and, consequently, an improvement in sneezing and
rhinorrhea as well as nasal obstruction. It could be also
suggested that ramatroban stabilizes mast cells or
decreases the metabolism of arachidonic acid so that the
amount of mediators released decreases. In contrast,
there is a report that TXA2 receptors may be present only
in blood vessels.2 If this is the case, another possible
explanation for the results of the present study is that the
broad improvement in symptoms following ramatroban
could be a result of the inhibitory effects on vascular
permeability and eosinophil infiltration, which is consist-
ent with the overall results of the antigen challenge test.
However, the decrease in histamine concentration in the
same antigen challenge test cannot be fully explained by
this speculation. Therefore, for the time being, no evident
explanation can be given for the broad beneficial effects
of ramatroban on the clinical symptoms of allergic
rhinitis, as well as hypersensitivity of the nasal mucosa.
The detailed pharmacological mechanism and clinical
outcomes of ramatroban should be investigated further.
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